Alopecia areata is a chronic inflammatory non-scarring condition affecting the hair follicle that leads to hair loss ranging from small well defined patches to complete loss of all body hair. In about 80% of affected individuals there is spontaneous regrowth within a year. It can present at any age, although 60% of patients develop their first episode of hair loss before the age of 20. There is a family history of alopecia areata in 20% of cases indicative of a genetic basis. A positive family history is prognostic of troublesome alopecia areata, as are onset in childhood, ophiasis (involvement of the scalp hair margins), nail changes and concurrent atopic disease. However, the severity of hair loss at presentation appears to be the strongest predictor of long-term outcome. There is an association with autoimmune diseases, including vitiligo, diabetes, pernicious anaemia and thyroid disease, suggesting that alopecia areata itself is an autoimmune disease, although this is still unproven. Alopecia areata normally presents with hair loss in discrete, well circumscribed patches, which may be small (<1 cm) to very large. Close examination of the periphery of a lesion with a magnifying glass will often reveal short hairs which taper in diameter from their tip to the point at which they emerge from the skin. These 'exclamation mark' hairs are diagnostic of alopecia areata. Individuals with alopecia areata should be referred for dermatological advice if there is diagnostic uncertainty, they have extensive hair loss, they are suffering severe psychological distress or they would like a wig.
Download full-text PDF |
Source |
---|
Front Immunol
January 2025
Department of Dermatology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, United States.
Autoimmune diseases (AID) are defined by immune dysregulation characterized by specific humoral and/or cell mediated responses directed against the body's own tissues. Cytokines in particular play a pivotal role in the pathogenesis of AID, with proinflammatory cytokines contributing to the initiation and propagation of autoimmune inflammation, whereas anti-inflammatory cytokines facilitate regression of inflammation and recovery from acute phases of the disease. Parallel work by our group evaluating a comprehensive set of pro- and anti-inflammatory serum cytokines in Pemphigus vulgaris (PV) as well as Alopecia areata (AA) uncovered a similar pattern of inheritance specific immune dysregulation in these two distinct autoimmune skin diseases.
View Article and Find Full Text PDFJ Dermatolog Treat
December 2024
Department of Dermatology, Beijing TongRen Hospital, Capital Medical University, Beijing, China.
Aim: To present three cases of filler-induced alopecia (FIA) and summarize the current knowledge of its clinical features, mechanisms and treatments.
Methods: In the first two cases, two females developed well-defined triangular patches of hair loss after hyaluronic acid (HA) injections, and received corticosteriod injections with topical 5% minoxidil. The third case described another female who experienced alopecia areata-like hair loss after autologous fat grafting, and received combined therapies including corticosteriod, 5% minoxidil and microneedling.
J Dermatolog Treat
December 2025
Center for Translational Dermatology, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Methods: A literature search was conducted on Drugs@FDA: FDA-Approved Drugs for the year 2024 to identify new dermatologic treatments.
Results: In 2024, the FDA approved seven new dermatologic therapies and expanded the indications for seven current therapies. These therapies treat conditions such as atopic dermatitis, hidradenitis suppurativa, prurigo nodularis, molluscum contagiosum, and alopecia areata, among others.
J Dermatol
January 2025
Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
Alopecia areata (AA) is a chronic, autoimmune skin disease characterized by non-scarring hair loss. Baricitinib, a Janus kinase inhibitor (JAKi), prevents hair loss and promotes hair regrowth by inhibiting the inflammatory Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway involved in cytotoxic T cell responses targeting hair follicles. The introduction of JAKi has transformed treatment against severe AA.
View Article and Find Full Text PDFFront Pediatr
January 2025
Department of Dermatology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang Province, China.
Alopecia areata (AA) is a common non-scarring hair loss condition whose specific pathogenesis is not yet fully understood. In children, AA often co-occurs with atopic dermatitis (AD), complicating treatment. Here, we report the case of a child with myasthenia gravis who had severe AA and moderate AD.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!